Jason
Pontin

When the Science Is Too Hard to Read, That's Usually the Signal

In 2018, Jason Pontin's brother-in-law, an artist named Joe Heaps Nelson, died from glioblastoma. The treatments available to him were essentially what they'd been decades before. Pontin, then settling into his role as Senior Partner at Flagship Pioneering - Moderna's parent company - understood the gap between what science could theoretically accomplish and what it was actually delivering. Two years later, he co-founded Totus Medicines with Neil Dhawan. The company can screen billions of small molecules against thousands of cellular targets in a single experiment - finding effective drug candidates thousands of times faster than traditional methods at a fraction of the cost. Its primary target is IDH1 inhibition for glioblastomas and astrocytomas.

This is the Pontin method: turn a hard problem personal, then build something to solve it. It's how he approached MIT Technology Review. It's how he approaches a board meeting. And it's how he thinks about the role of a venture capitalist in deep tech - not as a financial allocator picking winners, but as someone who understands what winning even means.

From the North Coast to Keble College

Born in London on May 11, 1967, to a British businessman father and a South African actress mother, Pontin was raised in Northern California - first in Berkeley, then on a farm on the North Coast. He attended Harrow School, one of England's most elite boarding schools (alumni include Winston Churchill), before reading Humanities at Keble College, Oxford. He graduated with both B.A. and M.A. degrees.

A humanities graduate making a career in technology journalism is a slightly unusual move. Pontin never pretended otherwise. What he brought from Oxford wasn't engineering fluency but something arguably rarer: the ability to ask why something matters, not just how it works. That sensibility would define three decades of work.

Red Herring and the Dot-Com Years

In 1996, Pontin became Editor of Red Herring Magazine, which covered the technology industry at the height of the dot-com boom. At its peak, the operation released two 500-page books monthly and hosted six major conferences each year. He helped build one of the first daily news websites in publishing - a genuinely radical act in 1997. Then the bubble burst. Red Herring collapsed in 2002. Pontin watched an entire media ecosystem implode, and drew conclusions about technology cycles that would inform everything that came after.

Rather than retreating, he founded The Acumen Journal of Life Sciences (2002-2004), a magazine examining biotechnology's impact on business, politics, and society. Its contributors included Horace Freeland Judson, Sherwin Nuland, and Jerome Groopman. Pontin was already orienting toward biology - nearly two decades before "computational biology" became a venture capital category.

Thirteen Years at MIT Technology Review

In July 2004, Pontin was hired as Editor of MIT Technology Review. By August 2005, he was also Publisher. He stayed for thirteen years.

What he inherited was a 104-year-old institution with a proud history and a model built for a world that no longer existed. What he left behind was a digitally native, globally recognized publication with genuine authority over the conversation about technology and society. In October 2012, he renamed the organization and relaunched it as a digital-first company - not a print publication that also had a website, but a media company that happened to still print issues.

In 2015, Pontin founded MIT Solve, MIT's open innovation platform, which deploys capital and resources toward addressing humanity's grand challenges. He served as Senior Advisor to MIT's 16th President Susan Hockfield and chaired the MIT Enterprise Forum, MIT's global entrepreneurial community. He wasn't just editing a magazine about technology's potential; he was testing that potential from inside one of the world's most consequential research institutions.

Flagship Pioneering and the Biotech Turn

After leaving MIT Technology Review in 2017, Pontin joined Flagship Pioneering as Senior Partner and Chief Editor. Flagship is Moderna's founding firm and one of the most productive biotech incubators in the world. For three years, Pontin led strategic communications for Flagship and its ecosystem, originated and developed new companies, and helped develop strategy for expanding the firm's domains of innovation.

Working inside a company that was creating vaccines, cancer therapies, and platform biotechnologies gave Pontin a ground-level view of what it takes to move science from a lab bench to a product that actually reaches people. He arrived at Flagship as a celebrated journalist and editor. He left as something harder to categorize: a person who understood both the narrative of deep tech and its operational reality.

General Partner at DCVC

In 2021, Pontin joined DCVC (Data Collective Venture Capital) in Palo Alto as General Partner. DCVC is a firm that backs early-stage companies using computation to transform large industries - biology, agriculture, climate, manufacturing, defense, and space. The fund has raised over $2 billion total, with the latest round closing at $700 million.

At DCVC, Pontin leads communications and originates investments in computational biology and chemistry. He is on the boards of companies working on problems at the frontier of what is currently possible: DNA synthesis, AI-driven drug discovery, water purification at industrial scale, lab automation, and more. His portfolio includes companies that have announced partnerships worth billions with major pharmaceutical firms.

Strateos, which Pontin chairs, is advancing robotic laboratories that allow scientists to run experiments remotely. Relation Therapeutics, where Pontin is a board member, uses single-cell genomics and machine learning to identify disease biology at previously impossible resolution - and in 2024 announced a collaboration with Novartis worth up to $1.7 billion, followed by an $108 million deal with GSK.

On the Board, and on the Record

Pontin remains a prolific communicator. He posts regularly on X/Twitter (@jason_pontin, 26,000+ followers) and on Bluesky, navigating the platform wars with the same equanimity he brought to media's digital transition. He contributes to DCVC's thought leadership on deep tech investing. His personal website (jasonpontin.com) houses decades of journalism, essays, and speaking work.

The through-line across everything is a question his 2013 TED Talk posed explicitly: can technology actually solve the big problems? Pontin's answer was then, and remains, carefully conditional. It depends on whether the problem is well-defined. It depends on whether the political and social will exists to pursue the solution. And it depends on whether the people building the companies have thought clearly about what they're actually trying to do.

He divides his time between Palo Alto and London, maintaining roots on both sides of the Atlantic - a British-Californian who has spent thirty years reporting on, then building, then funding the technologies that are supposed to matter most.